Miki Ando is a certified hematologist with over sixteen years of experience in research and patient care. She started her research focusing on improving treatment of NK cell neoplasms and obtained a Ph.D. in 2005. From 2011, she joined the Center for Cell and Gene Therapy at Baylor College of Medicine working with Dr. Malcolm K. Brenner as a postdoctoral fellow, and her work focused on an inducible caspase9 (iC9) delivery-system for lung cancer treatment. After she returned to Japan, she worked at Dr. Nakauchi’s laboratory at The Institute of Medical Science, The University of Tokyo. She obtained a Japan Society for the Promotion of Science (JSPS) Fellowship in 2015, and she continues her research on iC9, using it as a safeguard system for iPSC-derived T cell therapy. She has demonstrated in vivo efficacy and safety of iPSC-derived Epstein-Barr virus (EBV) specific cytotoxic T-lymphocytes (CTLs) against EBV-induced tumors, and her research now focuses on application of this novel immunotherapy in clinical use. Since April 2016, she is an associate professor of the Department of Transfusion Medicine and Stem Cell Regulation at Juntendo University School of Medicine.